Reports Q1 revenue $13.19M, consensus $9.59M. “In the first quarter, we advanced our innovative pipeline of clinical product candidates. Notably, we dosed the first patient in our Phase 2 LINNET study of lorigerlimab, which will evaluate patients with platinum-resistant ovarian cancer and clear cell gynecologic cancers. We believe lorigerlimab, a differentiated bispecific checkpoint inhibitor, may be uniquely positioned to address the significant unmet need in both indications,” said Scott Koenig, president and CEO of MacroGenics (MGNX). “We are focused on continued clinical execution this year and look forward to sharing our progress, including a clinical update from the LORIKEET Phase 2 study in the second half of 2025.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGNX:
- MGNX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- MacroGenics price target lowered to $2 from $4 at H.C. Wainwright
- MacroGenics: Hold Rating Amidst Development Halts and Financial Challenges
- MacroGenics Inc’s 2024 Earnings Call Highlights
- MacroGenics Hold Rating: Uncertainty in Pipeline and Fair Valuation Amidst Anticipated 2025 Updates
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue